Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis' Zelnorm has shown promise in a study demonstrating that it is a safe and efficacious medical treatment for patients with irritable bowel syndrome with a mixed bowel pattern.
Subscribe to our email newsletter
This is the first study to identify a potential treatment option for patients who suffer from this variation of irritable bowel syndrome (IBS). The findings were presented at Digestive Disease Week 2006.
IBS is a dysmotility and sensory disorder characterized by abdominal pain or discomfort, bloating, and altered bowel function. IBS patients are classified based on their primary bowel complaint as either IBS with constipation (IBS-C) or IBS with diarrhea (IBS-D).
Those IBS sufferers who do not fulfill scientifically based standards for either IBS-C or IBS-D can exhibit a mixed bowel pattern, or IBS-Mixed (IBS-M). A recent study of IBS sufferers published in the journal Gastroenterology revealed that nearly one third of participants experienced IBS-M.
“These study results are promising as Zelnorm was shown to provide a statistically significant improvement in satisfactory relief of IBS symptoms in both the IBS-C and IBS-M groups. More than 50% of the IBS-M patients experienced a response to tegaserod.”
Zelnorm is approved by the FDA for chronic idiopathic constipation and IBS with constipation.